Courtney Aldrich

Courtney Aldrich is a Professor in the Department of Medicinal Chemistry at the University of Minnesota College of Pharmacy. She serves as Director of High Throughput Screening at the Institute for Therapeutics Discovery and Development (ITDD). Dr. Aldrich maintains an active research program with over 310 research outputs and 37 funded projects spanning more than 20 years.

Dr. Aldrich received her PhD in Chemistry from the University of California Los Angeles in 2001 and her Bachelor's degree in Chemistry from the University of Missouri St. Louis in 1994. Her scholarly journey demonstrates consistent excellence in medicinal chemistry and drug discovery.

Her research focuses on medicinal chemistry approaches to drug discovery, with particular emphasis on tuberculosis therapeutics, bacterial metabolism, and enzyme inhibition. Dr. Aldrich's work centers on Mycobacterium tuberculosis, siderophore production, biotin metabolism, and adenylation enzymes. Her fingerprint analysis reveals strong expertise in pharmacology, biochemistry, and molecular biology related to infectious disease targets.

Analysis of her recent publications (2021-2025) shows a clear trajectory in antibacterial and antifungal drug discovery, with particular focus on tuberculosis therapeutics, enzyme inhibition strategies, and metabolic pathway targeting. Her work spans structural biology, medicinal chemistry, and microbiology, demonstrating interdisciplinary approaches to drug discovery challenges. Recent publications highlight work on biotin synthases, siderophore production, and rifamycin analogues.

• Director of High Throughput Screening at ITDD
• Principal Investigator on multiple NIH-funded projects
• Active collaboration across multiple institutions and disciplines

Dr. Aldrich currently leads multiple active research projects including 'Calmodulin and regulation of Cardiac Ryanodine Receptor and CaMKII' (2025-2028), 'Development of a novel broad spectrum antifungal therapeutic' (2023-2025), and 'Species specific optimization of rifamycins for nontuberculous mycobacterial lung disease' (2023-2025). Her laboratory maintains strong connections with pharmaceutical development and translational research initiatives.